Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells.
This study aimed to determine the long-term survival of 30 dendritic cell (DC) vaccinated patients with metastatic renal cell cancer. Patients were treated with a therapeutic vaccination of pulsed DCs in one of three clinical phase I/II trials during the years 1999 - 2003. Patients were followed up until 191 months (mean 65 days after DC therapy), when all patients had died. Total response to treatment was 40% with partial remission in 3%, mixed response in 7% and stable disease in 30%. The progressive disease rate was 60%. Long-term survival ranged from 3 to 191 months, with a mean survival of 59 months. Interestingly, patients who were treated previously with another form of immunotherapy showed a significantly improved probability of surviving. Mean long-term survival from the beginning of DC therapy was 21 months (1 to 75 months). Patients treated with DC vaccination seem to have a benefit in long-term survival.